Community Research and Development Information Service - CORDIS

Results 1 - 10 of 561
Order by: Results/page:
12 3 4 5 6 7 8 9 10 > >| 
The NGF system and its interplay with endocannabinoid signalling, from peripheral sensory terminals to the brain: new targets for the development of next generation drugs for neuropathic pain
ID: 603191
Start date: 2014-04-01, End date: 2017-12-31
So far, there are no effective treatments for neuropathic pain (NP), and current treatments suffer from serious unwanted side effects. The NGF ligand-receptor system has recently emerged as a novel target for NP of great therapeutic potential, a master regulator, controlling ...
Programme: FP7-HEALTH
Record Number: 185456
Last updated on: 2017-10-06
Advanced Studies towards Knowledge on Lyssavirus Encephalitis
Pathogenesis Improving Options for Survival
ID: 602825
Start date: 2013-11-01, End date: 2016-10-31
The overall aim of ASKLEPIOS is to unravel and increase our understanding of the mechanisms that govern pathogenesis of rabies virus (RABV) infection, in pursuit of the rational identification of novel therapeutic leads for rabies encephalitis. Several studies have been condu...
Programme: FP7-HEALTH
Record Number: 109348
Last updated on: 2017-10-06
The development of a novel therapeutic vaccine for the selective treatment of the autoimmune disorder, Graves’ disease
ID: 602779
Start date: 2013-12-01, End date: 2018-06-30
This aim of the DAVIAD proposal is to develop a therapeutic vaccine for Graves’ disease (GD) that has a better safety and efficacy profile than current treatments. There is a high level of unmet need in the treatment of Graves’ disease especially in patients with Graves orbit...
Programme: FP7-HEALTH
Record Number: 110669
Last updated on: 2017-10-06
Benznidazol and Triazol REsearch group for Nanomedicine and Innovation on Chagas diseasE
ID: 305937
Start date: 2012-09-01, End date: 2018-08-31
The BERENICE consortium is aiming at providing a new and cost-effective solution to a better treatment for Chagas chronic patients. Please see its objectives below : Main objective • Obtain a more effective, better tolerated and cheaper formulation of a drug with trypanocidal...
Programme: FP7-HEALTH
Record Number: 106038
Last updated on: 2017-10-06
Human stem cell applications for the treatment of hearing loss
ID: 603029
Start date: 2013-11-01, End date: 2017-10-31
Hearing impairment is the most frequent human sensory deficit and is mainly caused by the irreversible loss of neurosensory cells in the cochlea. The lack of human otic cell models represents a significant roadblock that has hampered the development of drug-based or cell-base...
Programme: FP7-HEALTH
Record Number: 110640
Last updated on: 2017-09-24
Neurobiology and Treatment of Adolescent Female Conduct Disorder: The Central Role of Emotion Processing
ID: 602407
Start date: 2013-09-01, End date: 2018-02-28
Conduct Disorder (CD) and Oppositional Defiant Disorder with symptoms of Conduct Disorder (which is included among the abbreviation “CD” throughout the proposal) has a highly negative impact for the affected individual as well as for families and society. Although the number ...
Programme: FP7-HEALTH
Record Number: 110199
Last updated on: 2017-09-24
Human pluripotent stem cell differentiation, safety and preparation for therapeutic transplantation in Huntington’s disease
ID: 602245
Start date: 2013-10-01, End date: 2018-03-31
This project will tackle the huge complexity of taking stem cell therapies to clinical application for neurodegenerative disease by focusing on selective differentiation of a single neuronal phenotype (medium spiny striatal neuron: MSN) for a single well-defined disease (Hunt...
Programme: FP7-HEALTH
Record Number: 109572
Last updated on: 2017-09-24
Development and clinical trials of a new Software ENgine for the Assessment & Optimization of drug and non-drug Therapy in Older peRsons
ID: 305930
Start date: 2012-10-01, End date: 2018-06-30
The European population of older people with multiple chronic diseases (multimorbidity) is increasing steadily in tandem with the rising population of people aged ≥ 65 years. Older multimorbid people are at high risk of polypharmacy (PP), inappropriate prescribing (IP), adver...
Programme: FP7-HEALTH
Record Number: 105397
Last updated on: 2017-09-24
Reach  α-synuclein-dependent neurodegeneration: clinical development of therapeutic AFFITOPE vaccines for Parkinson’s disease and multisystem atrophy
ID: 602999
Start date: 2013-10-01, End date: 2017-09-30
The goal of SYMPATH is to advance clinical development of therapeutic vaccines targeting α-synuclein (aSyn)-driven neurodegenerative diseases (ND). It addresses Parkinson’s disease (PD) and multiple system atrophy (MSA), two synucleopathies, for which no causal therapy exists...
Programme: FP7-HEALTH
Record Number: 109923
Last updated on: 2017-09-10
Platform for sharing best practices for management of rare diseases
ID: 305690
Start date: 2013-01-01, End date: 2016-12-31
RARE-Bestpractices will develop a sustainable networking platform, supporting the collection of standardized and validated data and efficient exchange of knowledge and reliable information on rare diseases (RD). RD are characterized by low prevalence (EU – 5:10000 persons). T...
Programme: FP7-HEALTH
Record Number: 105806
Last updated on: 2017-09-10
12 3 4 5 6 7 8 9 10 > >| 
List retrieved on: 2017-10-20
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top